ArticleEuropean journal of immunology2016
Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production.
Article in European journal of immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 54 citations in OpenAlex.
- Altered tissue specialized pro-resolving mediators in chronic rhinosinusitis.Prostaglandins, leukotrienes, and essential fatty acids · 2021Trial
- Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study.The Journal of nutritional biochemistry · 2018Trial
- Targeted Delivery of Specialized Pro-Resolving Mediators (SPMs) for Improved Treatments of Inflammatory Diseases and Cancer.Pharmaceutics · 2026Review
- Associations Between Serum Resolvin D1 Levels and Food Allergy Persistence in Children.Allergy, asthma & immunology research · 2026Article
- Specialized Pro-Resolving Lipid Mediators in Pulmonary Diseases: Molecular and Therapeutic Implications.Molecules (Basel, Switzerland) · 2025Review
- 1-stearoyl-2-arachidonoyl-driven B Cell metabolic dysregulation in chronic rhinosinusitis with nasal polyps: insights from Mendelian randomization and single-cell RNA sequencing.Frontiers in pharmacology · 2025Article
- Is Lipid Metabolism of Value in Cancer Research and Treatment? Part II: Role of Specialized Pro-Resolving Mediators in Inflammation, Infections, and Cancer.Metabolites · 2024Review
- Roles of Resolvins in Chronic Inflammatory Response.International journal of molecular sciences · 2022Review
- Cord blood sphingolipids are associated with atopic dermatitis and wheeze in the first year of life.The journal of allergy and clinical immunology. Global · 2022Article
- Specialized pro-resolving mediators as modulators of immune responses.Seminars in immunology · 2022Review
- Role of Specialized Pro-Resolving Mediators in Modifying Host Defense and Decreasing Bacterial Virulence.Molecules (Basel, Switzerland) · 2021Review
- Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?International journal of molecular sciences · 2021Review
- Marginating transitional B cells modulate neutrophils in the lung during inflammation and pneumonia.The Journal of experimental medicine · 2021Article
- Hormonal Dysregulation and Unbalanced Specialized Pro-Resolving Mediator Biosynthesis Contribute toward Impaired B Cell Outcomes in Obesity.Molecular nutrition & food research · 2021Review
- Regulation of T-Cell Immune Responses by Pro-Resolving Lipid Mediators.Frontiers in immunology · 2021Review
- Oxylipin Response to Acute and Chronic Exercise: A Systematic Review.Metabolites · 2020Review
- The Role of Endogenous Eicosapentaenoic Acid and Docosahexaenoic Acid-Derived Resolvins in Systemic Sclerosis.Frontiers in immunology · 2020Review
- Omega 3 Fatty Acid and Skin Diseases.Frontiers in immunology · 2020Review
- Biosynthetic metabolomes of cysteinyl-containing immunoresolvents.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Frontline Science: A reduction in DHA-derived mediators in male obesity contributes toward defects in select B cell subsets and circulating antibody.Journal of leukocyte biology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Specialized proresolving mediators (SPMs) constitute a recently recognized class of bioactive molecules thatpromote the resolution of inflammation. We recently reported that the SPMs resolvin D1 (RvD1) and 17-hydroxydocosahexaenoic acid (17-HDHA) promote the differentiation of IgG-secreting B cells and enhance antibody-mediated immune responses. However, there is an important knowledge gap regarding whether or not SPMs regulate human B-cell IgE production, which is the key effector in diseases such as asthma and allergy. Therefore, we investigated whether a panel of diverse SPMs influences B-cell IgE production. An important finding was that 17-HDHA and RvD1 inhibit IgE production by human B cells and suppress the differentiation of naïve B cells into IgE-secreting cells by specifically blocking epsilon germline transcript. This effect is specific to human IgE, as the SPMs do not inhibit production of IgM and IgG and did not suppress other IL-4-upregulated genes. 17-HDHA and RvD1 act by stabilizing the transcriptional repressor B-cell lymphoma 6, which competes with STAT6 for binding at the epsilon germline transcript promoter. Overall, these new findings demonstrate that certain SPMs inhibit the differentiation of IgE-producing B cells, without being broadly immune suppressive, representing a novel class of potential therapeutics for IgE-driven diseases such as asthma and allergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.